WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways

Philip W. Rouadi, MD\textsuperscript{a,*}, Samar A. Idriss, MD\textsuperscript{a,b}, Jean Bousquet, MD, PhD\textsuperscript{c,d,e,f}, Tanya M. Lidlaw, MD\textsuperscript{g}, Cecilio R. Azar, MD\textsuperscript{h,i,j}, Mona Sulaiman AL-Ahmad, MD, FAAAIAI, FRCPC\textsuperscript{k}, Anahi Yáñez, MD\textsuperscript{l}, Maryam Ali Y. AL-Nesf, MD, MSc, R, CABHS\textsuperscript{m}, Talal M. Nsouli, MD, FACAIAI, FAAAIAI\textsuperscript{n}, Sami L. Bahna, MD, DrPH\textsuperscript{o}, Eliane Abou-Jaoude, MD\textsuperscript{p}, Fares H. Zaitoun, MD, FACAAIAI, Usamah M. Hadi, MD, FACS, ERS, PARSAI\textsuperscript{q}, Peter W. Hellings, MD, PhD\textsuperscript{r,s,t,u}, Glenis K. Scadding, MD, FRCP\textsuperscript{v}, Peter K. Smith, BMedSci, MBBS, FRACP, PhD\textsuperscript{w}, Mario Morais-Almeida, MD\textsuperscript{x}, R. Maximiliano Gómez, MD, PhD\textsuperscript{y}, Sandra N. González Díaz, MD, PhD\textsuperscript{z}, Ludger Klimek, MD, PhD\textsuperscript{aa}, Georges S. Juvelekian, MD, FCCP, D’ABSM\textsuperscript{ab}, Moussa A. Riachy, MD, FCCP\textsuperscript{ac}, Giorgio Walter Canonica, MD\textsuperscript{ad}, David Peden, MD\textsuperscript{ae}, Gary W. K. Wong, MD\textsuperscript{af}, James Sublett, MD\textsuperscript{ag}, Jonathan A. Bernstein, MD\textsuperscript{ah}, Lianglu Wang, MD\textsuperscript{ai}, Luciana Kase Tanno, MD, PhD\textsuperscript{aj,ak}, Manana Chikhladze, PhD\textsuperscript{al}, Michael Levin, MD, PhD\textsuperscript{am}, Yoon-Seok Chang, MD, PhD\textsuperscript{an}, Bryan L. Martin, DO\textsuperscript{ao}, Luis Caraballo, MD, PhD\textsuperscript{ap}, Adnan Custovic, MD, PhD\textsuperscript{aq}, José Antonio Ortega-Martell, MD\textsuperscript{ar}, Erika Jensen-Jarolim, MD\textsuperscript{as,at}, Motohiro Ebisawa, MD, PhD\textsuperscript{au}, Alessandro Fiocchi, MD\textsuperscript{av} and Ignacio J. Anstotegui, MD, PhD\textsuperscript{aw}.

ABSTRACT

Background: Cough features a complex peripheral and central neuronal network. The function of the chemosensitive and stretch (afferent) cough receptors is well described but partly understood. It is speculated that chronic cough reflects a neurogenic inflammation of the cough reflex, which becomes hypersensitive. This is mediated by neuromediators, cytokines, inflammatory cells, and a differential expression of neuronal (chemo/stretch) receptors, such as transient receptor potential (TRP) and purinergic P2X ion channels; yet the overall interaction of these mediators in neurogenic inflammation of cough pathways remains unclear.

Objectives: The World Allergy Organization/Allergic Rhinitis and its Impact on Asthma (WAO/ARIA) Joint Committee on Chronic Cough reviewed the current literature on neuroanatomy and pathophysiology of chronic cough. The role of TRP ion channels in pathogenic mechanisms of the hypersensitive cough reflex was also examined.

Outcomes: Chemoreceptors are better studied in cough neuronal pathways compared to stretch receptors, likely due to their anatomical overabundance in the respiratory tract, but also their distinctive functional properties. Central pathways are important in suppressive mechanisms and behavioral/affective aspects of chronic cough. Current evidence strongly suggests neurogenic
inflammation induces a hypersensitive cough reflex marked by increased expression of neuromediators, mast cells, and eosinophils, among others. TRP ion channels, mainly TRP V1/A1, are important in the pathogenesis of chronic cough due to their role in mediating chemosensitivity to various endogenous and exogenous triggers, as well as a crosstalk between neurogenic and inflammatory pathways in cough-associated airways diseases.

**Keywords:** TRP channel, P2X3, Pathogenesis, Chronic cough, Chemoreceptors, Mechanoreceptors

**INTRODUCTION**

Persistent coughing lasting for ≥8 weeks in adults or 4 ≥ weeks in children can be defined as chronic cough, although prolonged acute cough can persist for 3 to 8 weeks in children. The physiologic cough reflex has well-defined vagus nerve-mediated afferent and efferent neuroanatomical and signal pathways. The peripheral afferent cough receptors, namely the chemosensitive and stretch receptors, are selectively distributed along the airways. They also manifest different triggers and functions (Table 1). Current research suggests that stimulation of these hyperreactive afferent vagus nerve endings can result in chronic cough, the so-called hypersensitive cough reflex (HCR). HCR manifests as variable lower than normal trigger thresholds to cough in various inflammatory and non-inflammatory airways pathologies and gastroesophageal reflux-related diseases. These trigger thresholds can be assessed by topical and inhalation tussigen challenges. HCR, however, can also occur in the absence of known triggers. Based on clinical models, it is speculated the underlying mechanism of HCR is a concomitant neurogenic and inflammatory pathological alteration of the cough reflex which becomes hypersensitive. Moreover, HCR in different anatomical regions is associated with a plethora of biomarkers which can be expressed individually or act collectively. These encompass neuronal receptors such as transient receptor potential (TRP) and purinergic P2X ion channels, exogenous and endogenous neuromediators, and cytokines and inflammatory cells. The current part I of the consensus (see Appendix) examines the neuroanatomical pathways, pathogenic mechanisms, and the role of TRP ion channels in modulation of chronic cough. The different phenotypes of abnormal cough presentation and their management will be published subsequently in part II and III of the consensus, respectively.

**APPLIED ANATOMY AND PHYSIOLOGY OF COUGH STRETCH AND CHEMORECEPTORS**

Cough reflex entails a physiological halt of the central “respiratory generator pattern” of normal respiration, in parallel with activation of the medullary premotor and motor neuronal pathways which initiate cough, collectively called the “cough generator pattern.”

**Peripheral afferent cough pathway**

Two parallel vagal afferent pathways of cough reflex originate in the nodose and the jugular ganglia. These have different embryological origins and distinct peripheral anatomical distributions (see Table 1) at which therapeutic trials are directed when investigating chronic cough. This approach is collectively called the “anatomic-diagnostic protocol” for cough management.

**Chemoreceptors**

Both jugular and nodose ganglia have chemosensitive (nociceptive) neurons which are unmyelinated C fibers, mainly sensitive to chemical stimuli and lung inflammation (Table 1). These chemoreceptors are associated with TRP ion channels, constitute the majority of airway afferent neurons in the lung and nose and innervate the lower respiratory tract from the
larynx to alveoli. Their activation causes airway constriction and mucus secretion, cough, and sneezing. The serious signs and symptoms of apnea, bradycardia, and hypotension can also be activated via these ganglia. Data suggest that chemoreceptors (eg, TRP-Vanilloid-1) are stretch-insensitive; however, they can also act as high threshold mechanoreceptors when activated by severe mechanical stimuli such as lung hyperinflation and aggressive touch stimuli. Despite lack of solid evidence, a “two pathways model” of cough has been suggested, whereby jugular chemo-sensitive receptors initiate cough in the proximal airways, whereas nodose chemosensory activation in the distal airways can inhibit cough. This is based on the fact that some mediators such as the cellular breakdown byproduct adenosine triphosphate (ATP) and serotonin, both of which are selective activators of nodose-chemosensitive neurons, are not potent tussigens. In summary, chemoreceptors can have a dual tussive role in view of their high sensitivity (low threshold) to inhaled chemicals, but also low activation (high threshold) by severe mechanical stimuli.

**Stretch receptors**

Nodose ganglia, but not jugular ganglia, incorporate stretch (mechanical) receptors which can be rapidly- (RARs) or slowly- (SARs) adapting stretch receptors and are present mainly in the distal airways. Their main function is protecting the airways from generally aspirated or inhaled matter. Stretch receptors are relatively insensitive to a wide range of chemical stimuli, although data to the contrary exist. RARs are mainly intrapulmonary dynamic receptors triggered by change in intrapulmonary airway mechanical properties, namely diameter, length, and interstitial pressures. Their activation triggers parasympathetically-mediated reflex bronchospasm and mucus secretion. The act of coughing and subsequent gasping inhalation can provoke RAR-stretch receptors and a pathogenic amplification loop. Contrary to their role in promoting bronchospasm, RARs can also attenuate cough. This is effected by counteraction of molecules which mediate bronchospasm in end organs, such as substance P and bradykinin, histamine, and capsaicin. This adds to the complexity of chronic cough. Similarly, bronchodilating agents such as prostaglandin (PG) E2, adrenaline, and adenosine can have a dual role. They can inhibit bronchospasm secondary to activation of RAR-stretch receptors by capsaicin and bradykinin. However, bronchodilators can also sensitize C fiber-chemoreceptors to capsaicin and bradykinin thereby promoting cough and bronchospasm. SARs are incorporated within the bronchioles and alveoli and have peak activity at end-inspiration when they initiate normal expiration through a centrally mediated inhibition of muscarinic respiratory drive. It is questionable whether SARs, RARs, or both contribute to the bronchoprotective (bronchodilating) effect of deep inspiration. The latter normally becomes suppressed in healthy subjects undergoing methacholine bronchoprovocation challenge. Nevertheless, stretch receptors can promote coughing through central activity at the level of the brainstem. In summary, stretch receptors initiate physiologic expiration and additionally can either trigger or attenuate cough by different pathogenic mechanisms.

Anatomical overlap of stretch and chemoreceptors

Mechano-receptors originating from nodose ganglia and carried by the vagus nerve can overlap with jugular chemo-sensory terminals in the proximal airways. Thus, the larynx, trachea, and main bronchi can be triggered by both mechanical and chemical stimuli. However, it is generally agreed stretch receptors are not activated by chemical stimuli except when mechanical distortion of nerve terminal occurs. This can be secondary to mucosal inflammation, mucus secretion, or alteration in smooth muscle tone. Based on animal studies, this overlapping subpopulation of nodose-stretch receptors and jugular-chemoreceptors is sensitive to rapid changes of pH and touch-like stimuli, hence their partial role in clearing the airways specifically from aspiration of food or gastric contents.
| Vagus nerve | Peripheral afferent distribution | Neuronal type | Triggers | Role | Chemical predilection/Muscarinic activity | Capsaicin challenge | Receptor agonist | Overlap of receptors in proximal airway |
|-------------|---------------------------------|---------------|----------|------|---------------------------------------|-------------------|-----------------|-------------------------------------|
|[Jugular ganglia](#) | - Main bronchus - Trachea - Lungs | C fibers (unmyelinated) | Chemicals and lung inflation* | Airway clearance of inhaled chemicals and inflammatory products | Chemical predilection to: - Nicotine - Hypertonic solution Muscarinic stimulatory role● | Cough hyper-responsiveness | Bradykinin | Overlap with stretch receptors |
| [Nodose ganglia](#) | - Bronchioles - Alveoli | C fibers (unmyelinated) | Chemicals and lung inflation* | Airway clearance of inhaled chemicals and inflammatory products | Chemical predilection to: - Adenosine triphosphate - Serotonin (exclusive) Muscarinic stimulatory role● | Cough hyper-responsiveness | Bradykinin | No overlap with stretch receptors |

### Chemoreceptors

**Jugular ganglia**
- Main bronchus - Trachea - Lungs
- C fibers (unmyelinated)
- Chemicals and lung inflation*

**Nodose ganglia**
- Bronchioles - Alveoli
- C fibers (unmyelinated)
- Chemicals and lung inflation*

### Stretch receptors (nodose ganglia)

**RARs**
- Intrapulmonary (majority)
- A-δ fibers
- Change in airway mechanical properties
- Airway clearance of inhaled matter and aspirated products
- Muscarinic stimulatory role●
- No response
- pH alteration
- Overlap with chemoreceptors

**SARs**
- Bronchioles - Alveoli
- A-δ fibers
- End-inspiratory cycle
- Airway clearance of inhaled matter and aspirated products
- Muscarinic inhibitory role
- No response
- pH alteration
- Overlap with chemoreceptors

*Chemoreceptors can act as high threshold mechano (stretch) receptors, ● bronchoconstriction, cough and mucus secretion, ○ Respiratory drive blockage and initiation of expiration

Table 1. Neuro-anatomical properties and functional role of cough chemosensitive and stretch receptors in vagal afferent neuronal pathways from human and animal clinical models.
thresholds to a range of chemical agents including those which trigger stretch receptors.

Central cough pathways

Centrally the afferent pathways of the nodose and jugular ganglia feature different brainstem projections, namely the nucleus solitarius and paratrigeminal nucleus, respectively\textsuperscript{32-34} (Fig. 1). Central cough mechanisms and specific regions involved are unknown. Moreover, ascending pathways from the brainstem to higher cortical areas can be studied with functional brain imaging.\textsuperscript{35,36} This imaging helps us understand the behavioral, sensory-discriminative, and affective-motivational aspects of airway irritation.\textsuperscript{37} Central descending pathways of the prefrontal cortical region are involved with urge-to-cough and the initiation of a voluntary cough or its suppression; this occurs in the presence or absence of a peripheral activation stimulus.\textsuperscript{38} For example, chronic cough patients were less able to suppress cough in response to capsaicin inhalation, when compared to healthy controls, reportedly due to failure of inhibitory descending pathways.\textsuperscript{39} In accordance, patients with chronic cough challenged with sufficient inhaled capsaicin to induce urge-to-cough demonstrated lower activation of cough inhibitory descending pathways by functional magnetic resonance imaging, compared to healthy subjects.\textsuperscript{40} Uregulation or downregulation of cough can occur centrally or peripherally. Central modulation of cough can be manifested by voluntary suppression of cough.\textsuperscript{37} Both central and peripheral modulation of cough are likely independent of a systemic airway inflammatory disease. This can partly explain the controversial role of atopy as a risk factor for chronic cough in the lower airways.\textsuperscript{41} In summary, central cough pathways account for behavioral/affective aspects of cough in addition to modulation of tussive effect as manifested by inhibition or suppression of voluntary cough and urge-to-cough. This is likely independent of a systemic airway inflammation.

**PATHOPHYSIOLOGY OF HYPERSENSITIVE COUGH REFLEX**

HCR is best described as a hyperexcitable neuroinflammation of the cough-triggering vagal neuronal pathway. This can occur centrally,\textsuperscript{42} peripherally or both,\textsuperscript{37,43} and is mediated by increased neuronal expression of TRP ion channels.\textsuperscript{44} Triggers, which in otherwise normal individuals do not necessarily exacerbate cough, can cause prolonged coughing in patients with HCR (Fig. 1). These triggers include normal human activity, changes in ambient atmospheric conditions, exposure to airborne irritants and pollutants, an acute infectious or atopic respiratory event, and a chronic inflammatory disease as well as with an experimental inhalation challenge with tussigens.

![Fig. 1](image-url)
Neurogenic dysfunction

Various triggers can induce acute, subacute, or chronic modification of excitability pattern in the cough central and likelyafferent neuronal pathway along the vagus nerve. This can result in exaggeration or suppression of cough reflex, a term called cough plasticity. Cough plasticity can be modified by the following factors: 1) the nature of triggering factors, 2) the ensuing modification in intrinsic neuronal excitability, 3) changes in neuronal synaptic transmission (pre- or postsynaptic), and 4) the subsequent effect of neurotransmitters and neuromodulators, such as the calcitonin gene-related peptide (CGRP), an important neuropeptide with pro-inflammatoryatory potential. Evidence suggests that cough plasticity involves primarily the (vagal) nucleus tractus solitarius, the associated higher central sensory processing circuit and the vagal afferent nerves. Also, it is speculated this abnormal excitability of central sensory neuronal pathways can exist even in the absence of a prior acute or chronic peripheral sensitization; this is very similar to chronic neuropathic pain which results in the “uncoupling of central cough hypersensitivity state to the injury zone.” In summary, cough plasticity refers to a peripheral/central variable cough threshold to nonspecific triggers, or their absence, and is driven partly by neurogenic mechanisms involving neuropeptides and neuromodulators, among others.

Immune alterations

In HCR, the term “neurogenic inflammation” implies cough is primarily a neurogenic response monitored by the immune system. Dysfunction of one or both systems can result in HCR. Direct or indirect release of inflammatory mediators has been reported into the nucleus tractus solitarius and adjacent medullary neuronal complex area. The intricate regulatory role of the immune system in HCR is deciphered by experimental in-vivo and in-vitro models comparing different cough phenotypes to each other or to healthy individuals. Based on specimen findings from broncho-alveolar lavage fluid, induced sputum and lung biopsies of patients with different cough phenotypes, studies suggest inflammatory cells such as eosinophils, neutrophils and mast cells are involved in the pathogenesis of cough. In fact, there is a considerable similarity in biochemical profile among patients with HCR (see below). A detailed description of immune cascade pathways in HCR is comprehensively described elsewhere. Importantly, in vivo and in vitro data from these reviews address the immune modulatory role of cough in a variety of lower airway clinical phenotypes of chronic cough but unfortunately most patient populations included in these studies are small in size. Neurokinins such as substance P, CGRP, and interleukins (IL)-4 and IL-5 stimulate eosinophils to release effector molecules such as major basic proteins, cysteinyi leukotrienes, and eosinophil granule-derived cationic proteins with resultant stimulation of cough sensory and muscarinic nerves. Nerve growth factor (NGF), whose main source in humans is eosinophils, increases expression of TRP channels (TRPV1, TRPA1) on sensory nerves with inflammation, thus highlighting the role of allergic airway inflammation in chronic cough. Similar modulation of cough can also be induced by IL-17-mediated infiltration of neutrophils whose probable role in neurogenic inflammation is generation of reactive oxygen species and sensitization of cough neuronal pathway. The same effect can result from bradykinin-induced secretion of PGs which are potent tussigens. Data also suggest an important role of mast cells in chronic cough patients. Patients with non-asthmatic cough have marked submucosal mast cell infiltration as opposed to patients with asthmatic cough with submucosal infiltration by neutrophils and eosinophils. CGRP, a byproduct of neurogenic inflammation of sensory nerves, induces mast cell hyperplasia. These cells, which are in close association with airway mucosal sensory nerves, highlight the role of the innate immune system in regulating neurogenic inflammation in respiratory epithelium of chronic cough patients. For example, increase in histamine and PGD2 in sputum specimens of patients with non-asthmatic eosinophilic bronchitis compared to asthmatics suggests that mast cell are particularly activated in the former cough phenotype. Meanwhile, data from clinical trials using biological therapy undermine the role of eosinophils in HCR. For example, anti-IL-5 treatment improved cough scores in asthmatics, but not markers of sputum eosinophilia. This speculates a more important role
of mast cells in asthmatic patients with cough. Along the same line, inhaled and nasal topical steroids improved markers of eosinophilic inflammation in cough-associated asthma/eosinophilic bronchitis, and allergic rhinitis/chronic rhinosinusitis with nasal polyps, respectively. Taken together, these data and others suggest airway eosinophilia can be an epiphenomenon in chronic cough, yet maintain evidence that eosinophilic airway inflammation identifies steroid-responsive patients. Other neuro-inflammatory mediators implicated in HCR such as IL-1β, tumor necrosis factor-α and NGF have an integral role in TRPV1 and TRPA1 gene production and channel expression. In conclusion, despite ample evidence of inflammatory and biochemical mediators of neurogenic inflammation being involved in different cough phenotypes, their exact role remains obscure. There seems to be an important role of mast cells and innate immune system in HCR. Yet, it is difficult to clearly delineate the signal and cascade pathways involved in different etiologies or phenotypes of chronic cough.

TRP CHANNELS IN COUGH NEURONAL PATHWAYS

Neuro-physiological properties

TRP channels are a collective family of ion channel receptors located at afferent airway cough neurons of the vagus and trigeminal nerves and mediate airway protective mechanisms to noxious stimuli (Fig. 1). They are present in the entire respiratory tract from the nose through to the alveoli and are expressed on neuronal and non-neuronal cells such as epithelium, fibroblasts, smooth muscle cells, and inflammatory cells. TRP expression on smooth muscle cells suggests their role also in mediating structural and functional changes in airway mucosal barrier as occurs, for example, in airway remodeling. Broadly speaking, TRPV1 (aka capsaicin receptor) and TRPA1 dominate the intra- and extra-pulmonary cough airway afferents, are carried on unmyelinated C fibers, and are chemosensitive, that is triggered by locally produced or inhaled chemicals and inflammatory mediators. On the other hand, airway sensitivity to mechanical, thermal, and pH-related stimuli is generally featured on a minority of airway cough afferents which are almost exclusively extrapulmonary (proximal airways), are carried on myelinated A-δ fibers, and are not mediated by TRPV1 channels.

Chemosensitivity

A thorough anatomical and functional description of TRP channels in different cough phenotypes is well described in the literature and summarized in Table 2. Chemoreceptors are the main TRP channels featured in the airways and are, in the majority, TRPV1 ion channels. These co-localize with neuropeptides, such as substance P, CGRP, and receptors for NGF. They also have low threshold for various inflammatory mediators such as bradykinins, histamines and eicosanoids. Simultaneous stimulation by multiple TRP channel agonists, such as occurs with capsaicin in the presence of gastric acid or fever, can further lower the activation threshold. In accordance, the simultaneous activations of TRPA1 and TRPV1 by their respective selective agonists on pulmonary sensory nerves are far more effective than single agonists taken separately. Chemosensitivity of TRPV1 and TRPA1 to endogenously generated chemicals such as bradykinin, arachidonic acid, and its effector, PGE2, coupled to G protein receptor activation occurs in inflammatory diseases, such as asthma. Oxidative stress mediators following exposure to air pollutants, such as cigarette smoke (acrolein), diesel exhaust particles, aldehydes, chlorines, and scents, can also trigger chemosensitive TRPA1 channels. Both TRPV1 and TRPA1 activate the mucin-producing MUC5 gene. In mammal models, a calcium mediated activation of TRP channels triggers local release of neuropeptides from afferent terminals peripherally or centrally. Ultimately, a signal is sent through efferent cholinergic pathways to cause bronchoconstriction in parallel with a vagal motor neuron-mediated signal to the larynx, accessory respiratory muscles and diaphragm to initiate cough and induction of various cellular responses. In summary, current data suggest airway chemosensitivity to endogenously produced and/or exogenously inhaled chemicals and inflammatory products is mediated by TRPA1/V1 channels. Central and peripheral mechanisms subsequently induce bronchoconstriction and cough.
| Trigger | TRPV1 | TRPA1 | TRPV4 | TRPM8 | P2X3 |
|---------|-------|-------|-------|-------|------|
| **Exogenous:** | | | | | |
| Environmental: | - High T (≥43 °C), | - Low T (<17 °C), | - Low to warm T (10-25 °C), | - Low to warm T (10-25 °C), | Endogenous: |
| - Painful stimuli, | - Painful stimulus, | - Painful stimuli | - Cooling compound (menthol, icilin and eucalyptol), | | - ATP |
| Dietary: | - TBS, herbicides, | - Citric acid, | - HRV | | (extracellular), |
| - Chili pepper (capsaicin), | - antsicid, | - Synthetic phorbol ester 4α- PDD, | | | - Thermal stimuli, |
| - Mustard, wasabi (allyl | - acrolein and | - Shear stress, | | | |
| isothiocyanate), | formaldein), | | | | |
| - Vanilloids, | **Endogenous:** | | | | |
| - HRV, | - Lipid and AA metabolites | | | | |
| **Endogenous:** | (e.g., PGE2), | | | | |
| - Bradykinin, | - Arachidonic acid metabolites, | | | | |
| - Nerve growth factors, | - Phospholipase A2 activation, | | | | |
| - Low pH (<5.9), | - Mechanical-osmotic changes | | | | |
| - Serotonin, | (hypo-osmolarity).110-113 | | | | |
| - Histamine, | **Others:** | | | | |
| - CGRP, | - TRPM8 activators, | | | | |
| - Cannabinoid and | **Endogenous:** | | | | |
| dopamine derivates, | - Lipid and AA metabolites (e.g., PG), | | | | |
| - ATP, | - Bradykinin | | | | |
| **Others:** | - Nerve growth | | | | |
| - Proteases, | factors, | | | | |
| - TRPA1.91-99 | - NO, | | | | |
| | - Reactive oxygen | | | | |
| | species, | | | | |
| | - Histamine, | | | | |
| | - Cytokines (e.g., TSLP), | | | | |
| | **Others:** | | | | |
| | - Proteases, | | | | |
| | - TRPV1.106-109 | | | | |

**Role in cough reflex** |
- Increase sensitivity to capsaicin, citric acid, histamine.118,119 |
- Increase sensitivity to capsaicin.120 |
- Insensitive to capsaicin.121 |
- Increase sensitivity to capsaicin, citric acid.122 |
- Increase sensitivity to capsaicin, citric acid, histamine.123-125

Rouadi et al. World Allergy Organization Journal (2021) 14:100617
doi.org/10.1016/j.waojou.2021.100617
### Airway Function

| Non-neuronal cellular mapping* | - Chemoreceptors (major), **Role in:** - Increased cytokine gene expression mediating bronchoconstriction - Transition of early defensive immune and inflammatory responses to chronic responses and disease pathology. | - Chemoreceptor, **Role in:** Bronchoconstriction secondary to irritant exposure. | - Polymodal ion channel, **Role in:** - Neurogenic inflammation - Ciliary beat frequency - Epithelial barrier function - macrophage activation. | - Cold thermal receptors (major), **Role in:** - Macrophage and T cell function, **Conflicting role in:** - Bronchoconstriction and cough in response to cold T, - Cough inhibition in lower airways by menthol effect on nasal neurons, - Airway epithelium production of mucus and inflammatory mediators. | - ATP- gated ion channel, **Role in:** - Nociception. |

### Cough phenotypes

| - Allergic rhinitis, - Asthma, - COPD. | - Asthma, - COPD. | - Asthma, - COPD. | - Cold induced-nasal hyperreactivity, - Cough and bronchoconstriction, - COPD. | - Asthma, - COPD. |

---

**Table 2.** Functional and tussive properties of P2X3 and important TRP channels in cough-associated airway diseases from in-vivo and in-vitro models. *cough pertinent non-neuronal tissues, AA (Arachidonic acid), ATP (Adenosine triphosphate), CGRP (Calcitonin gene-related peptide), COPD (Chronic obstructive pulmonary disease), HRV (Human rhinovirus), NO (Nitric oxide), PG (Prostaglandins), T (Temperature), TBS (Tobacco smoke), TSLP (Thymic stromal lymphopoietin), TRP (transient potential receptor)
Role in neurogenic inflammation, polymorphism, and cough suppression

As described earlier, TRP channels mediate neurogenic inflammation. They can respond differentially to inflammatory mediators and, through Ca-dependent mechanisms, can produce additional mediators. For example, stimulation of TRPV1 and TRPA1 can locally release neurotrophins important for chemotaxis and activation of eosinophils. Once activated, eosinophils secrete NGF resulting in recycling of TRP channels to surface membrane and increased expression of TRP channels resulting in an amplification loop. Ultimately, depolarization or hyperpolarization of TRP channels at nerve terminals can respectively increase or decrease excitability of cough afferent neuronal pathway. This crosstalk between inflammatory and neurogenic signal pathways highlights the role of TRP channels in several airway diseases. These can include post-viral cough, idiopathic cough, asthma, and chronic obstructive pulmonary disease, and other less frequent respiratory diseases such as idiopathic pulmonary fibrosis and airway Pseudomonas infection in cystic fibrosis. This same cross talk likely also occurs in COVID-19 cough. Due to their variable expression patterns in neurogenic inflammation, it is also suggested that TRP channels may be partly responsible for a transition from early (acute) defensive immune and inflammatory responses to chronic responses and chronic cough pathology. Unlike other TRP channels, TRPM8 can mediate a decrease in capsaicin-mediated cough sensitivity in the presence of thymol and camphor, which explains the antitussive effect of these agents, probably secondary to stimulation of cool receptors in the nasal cavity. TRP channel variants have been linked to altered cough presentation: TRPV1 polymorphisms have been associated with decreased wheezing in a group of asthmatics but a higher risk of chronic cough in both smokers and patients with occupational exposure. Other data suggest that TRPA1 polymorphism is associated with poor control of asthma secondary to air pollutant (particulate matter) exposure. Moreover, cough suppression can be mediated by TRP channels. Oral capsaicin was found to reduce cough by desensitization of TRPV1. Also, TRPA1 antagonist suppressed cough in guinea pigs yet TRPV1 or TRPA1 antagonists failed to suppress chronic cough in humans. This argues for involvement of central sensitization in HCR. In fact, data from P2X3 antagonists (see below) suggest central rather than peripheral neuronal pathways of vagus nerve are likely important target areas for new antitussive drug development. In conclusion, the anatomical and physiological mapping of TRP channels along cough neuronal pathways and their upregulation in neurogenic inflammation of cough reflex suggest their important role in pathogenesis of chronic cough. This is likely manifested by a crosstalk between neurogenic and inflammatory signal pathways in cough-associated airway diseases.

P2X3 CHANNELS IN COUGH NEURONAL PATHWAYS

P2X3 purinergic channels are receptors belonging to the P2X family of ion channels, with high predilection to the cellular breakdown product ATP. P2X3 channels are almost exclusively expressed on sensory neurons. Specifically, they are present, in their majority, on both C (chemoreceptors) and A-δ fibers (mechanoreceptors) of vagal afferent cough pathways with some expression in nucleus tractus solitarius. P2X3 receptor activation by adenosine triphosphate (ATP) depolarizes the peripheral cough neuronal pathway and transmits a central signal interpreted as urge-to-cough. P2X3 channels can also modulate the cough neuronal pathway activity at central synapses in both upper and lower airways, hence the effect of P2X3 antagonists. Mounting evidence suggests that P2X3 receptors can mediate HCR leading to chronic cough. However, it remains unclear if the role of P2X3 in HCR is secondary to increased ATP production in the airways or decreased ATP degradation, an enhanced sensitivity to ATP or a combination of these factors.

SUMMARY

This paper represents a comprehensive and updated review on neuroanatomy and pathophysiology of HCR, including novel findings on the role of TRP receptors and P2X channels in
modulating chronic cough. Knowledge of immune pathways involved in chronic cough is vital to understand how neurogenic inflammation of HCR, in different anatomical regions of the aero-digestive tract, can express different symptomatology, and thus results in different cough-associated clinical phenotypes. In chronic cough, there is a differential expression of chemo/stretch-sensitive afferent receptors (TRP channels) as well as P2X ion channels. Also neuromediators and inflammatory cells, such as mast cells, eosinophils, and neutrophils, are involved in HCR. It is likely that mast cells and innate immune system have a pivotal role in HCR, whereas current data undermine the role of eosinophils in chronic cough. An important function of TRP channels in chronic cough stems from data on TRP polymorphism and cough suppression by TRP antagonists. TRP channels can also mediate cross talk between neurogenic and inflammatory signal pathways involved in chronic cough. The nature of cough triggers, spectrum of expressed TRP channels and their co-localization with distinct neuro-inflammatory mediators, in addition to tussigen challenge data, contribute significantly to a proper diagnosis and treatment strategies of chronic cough. Currently, we lack a better functional understanding of cough central pathways and how they modulate chronic cough. Tussigen challenge protocols which can better discriminate healthy subjects from patients with HCR need to be standardized. This is more evident considering the value and limitations of animal cough models.

Abbreviations
ATP (Adenosine triphosphate), CGRP (Calcitonin gene-related peptide), HCR (Hypersensitive cough reflex), IL (Interleukin), NGF (Nerve growth factor), P2X (Purinergic receptors), PG (Prostaglandin), RAR (Rapidly adapting receptors), SAR (Slowly adapting receptors), TRP (Transient receptor potential).

Authors contributions
PR designed the plan of the article, contributed to the data collection. He wrote the manuscript draft, conceived, and designed the tables/figures, and reviewed all parts of the article.
SI contributed to data collection, tables/figures, and manuscript draft.
JB participated to the manuscript draft and reviewed the whole article.
TL, CA, MAA, AY, MAN, TN, SB, EAJ, FZ, UH, GJ and MR contributed the manuscript draft each according to his/her specialty and domain of interest.
The rest of authors reviewed closely the whole article and added their valuable remarks.

Availability of materials
Not applicable.

Ethics statement
Not applicable. This is a consensus paper rather than research.

Funding
Not applicable.

Declaration of competing interest
Jean Bousquet discloses financial relationships with the following entities: Purina, Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, KyoMed, MASK-air. Glenis Scadding discloses payment for talks from ALK, Bayer, GSK and Viatris. She is also chair/member of 3 Data Monitoring Committees for ALK. Jonathan A. Bernstein discloses he is PI and consultant and speaker for Merck. Erika Jensen-Jarolim discloses honoraria and support to attend meetings from Bencard Allergie, Germany, and Allergy Therapeutics Ltd, UK; a pending patent and stock or stock options with Biomedical Int. R + D GmbH, Vienna; participation on data monitoring or advisory boards with Allergy Therapeutics Ltd, UK; and receipt of equipment, materials, drugs, medical writing, gifts or other services from Bencard Allergie, Germany. Giorgio Walter Canonica discloses speaker or advisory board roles with Menarini, Chiesi, Sanofi, GSK, AstraZeneca, Novartis, Stallergenes, Hall, Allergy Therapeutics. All other authors indicated they have nothing to disclose related to the submitted work.

Acknowledgements
Not applicable.

Appendix A. Supplementary data
Supplementary data related to this article can be found at https://doi.org/10.1016/j.waojou.2021.100617.

Author details
aDepartment of Otolaryngology - Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon.
bDepartment of Audiology and Otoneurological Evaluation, Edouard Herriot Hospital, Lyon, France.
cHospital Charité, Universitätmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
dDepartment of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany.
eMacvia France, Montpellier France.
fUniversité Montpellier, Montpellier, France.
gDepartment of Medicine, Harvard Medical School, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital Boston, MA, USA.
hDepartment of Gastroenterology, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon.
iDepartment of Gastroenterology, Middle East Institute of Health (MEIH), Beirut, Lebanon.
Clemenceau Medical Center (CMC), Beirut, Lebanon.  
*Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait.  
Respiratory, Buenos Aires, Argentina.  
*Allergy and Immunology Section, Department of Medicine, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.  
*International Cough Institute, Washington D.C, USA.  
*Allergy & Immunology Section, Louisiana State University Health Sciences Center, Shreveport, LA, USA.  
*Department of Allergy Otolaryngology, LAU-RIZK Medical Center, Beirut, Lebanon.  
*Clinical Professor Department of Otolaryngology Head and Neck Surgery, American University of Beirut, Lebanon.  
*KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Allergy and Clinical Immunology, Leuven, Belgium.  
*University Hospitals Leuven, Department of Otorhinolaryngology, Leuven, Belgium.  
*University Hospital Ghent, Department of Otorhinolaryngology, Laboratory of Upper Airways Research, Ghent, Belgium.  
*Academic Medical Center, University of Amsterdam, Department of Otorhinolaryngology, Amsterdam, the Netherlands.  
*Department of ENT, RNENT Hospital, London, UK.  
*Clinical Medicine Griffith University, Southport Qld, 4215, Australia.  
*Allergy Center, CUF Descobertas Hospital, Lisboa, Portugal.  
*School of Health Sciences, Catholic University of Salta, Argentina.  
*Universidad Autónoma de Nuevo León, Hospital Universitario y Facultad de Medicina, Monterrey, Nuevo León, Mexico.  
*Center for Rhinology and Allergology, Wiesbaden, Germany.  
*Department of Pulmonary, Critical Care and Sleep Medicine at Saint George Hospital University Medical Center, Beirut, Lebanon.  
*Department of Pulmonary and Critical Care, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.  
*Humanitas University, Personalized Medicine Asthma & Allergy Clinic-Humanitas Research Hospital-IRCCS-Milano Italy.  
*UNC Center for Environmental Medicine, Asthma, and Lung Biology, Division of Allergy, Immunology and Rheumatology, Department of Pediatrics UNS School of Medicine, USA.  
*Department of Pediatrics, Chinese University of Hong Kong, Hong Kong, China.  
*Department of Pediatrics, Section of Allergy and Immunology, University of Louisville School of Medicine, 9800 Shelbyville Rd, Louisville, KY, USA.  
*University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati.  
*Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China.  
*Desbret Institute of Epidemiology and Public Health, UMR UA-11, INSERM University of Montpellier, Montpellier, France.  
*WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.  
*Medical Faculty at Akaki Tsereteli State University, National Institute of Allergy, Asthma & Clinical Immunology, KuTaisi, Tskaltubo, Georgia.  
*Division of Paediatric Allergology, Department of Paediatrics, University of Cape Town, South Africa.  
*Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.  
*Department of Otolaryngology, Division of Allergy & Immunology, The Ohio State University, Columbus, OH, USA.  
*Institute for Immunological Research, University of Cartagena.  
Cartagena de Indias, Colombia.  
*National Heart and Lung Institute, Imperial College London, UK.  
*Health Science Institute, Autonomous University of Hidalgo, Mexico.  
*Institute of Pathophysiology and Allergy Research Center, Pathophysiology, Infectiology and Immunology, Medical University Vienna, Austria.  
*The Interuniversity Messerli Research Institute, Medical University Vienna and Univ, of Veterinary Medicine Vienna, Austria.  
*Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.  
*Translational Pediatric Research Area, Allergic Diseases Research Unit, Bambino Gesù Children’s Hospital IRCCS, Rome, Holy See.  
*Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain.

REFERENCES

1. Irwin RS, French CL, Chang AB, Altman KW. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest. 2018;153(1):196–209. https://doi.org/10.1016/j.chest.2017.10.016.

2. Chang AB, Robertson CF, Van Asperen PP, et al. A cough algorithm for chronic cough in children: a multicenter, randomized controlled study. Pediatrics. 2013;131(5):e1576–1583. https://doi.org/10.1542/peds.2012-3318.

3. Chang AB, Anderson-James S, Marchant JM. Chronic cough in children. Clin Pulm Med. 2014;21(3):138-144. https://doi.org/10.1097/CPM.0000000000000037.

4. Weinberger M, Fischer A. Differential diagnosis of chronic cough in children. Allergy Asthma Proc. 2014;35(2):95-103. https://doi.org/10.2500/aap.2014.35.3711.

5. Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L. Anatomy and neurophysiology of cough: CHEST guideline and expert panel report. Chest. 2014;146(6):1633-1648. https://doi.org/10.1378/chest.14-1481.

6. Polverino M, Polverino F, Felino M, André F, Afri I, De Blasio F. Anatomy and neuro-pathophysiology of the cough reflex arc. Multidiscip Respir Med. 2012;7(1):1-5. https://doi.org/10.1186/2049-6958-7-5.

7. Reynolds SM, Docherty R, Robbins J, Spina D, Page CP. Adenosine induces a cholinergic tracheal reflex contraction in Guinea pigs in vivo via an adenosine A1 receptor-dependent mechanism. J Appl Physiol. 2008;105(1):187-196. https://doi.org/10.1152/japplphysiol.01048.2007.

8. Mazzone S. An overview of the sensory receptors regulating cough. Cough. 2005;1(2):1-9. https://doi.org/10.1186/1745-9974-1-2.

9. Plekova J, Song W-J. Chronic cough in subjects with upper airway diseases - analysis of mechanisms and clinical applications. Asia Pac Allergy. 2013;3(2):127-135. https://doi.org/10.5415/apallergy.2013.3.2.127.
10. Finsterer J, Grisold W. Disorders of the lower cranial nerves. J Neurosci Rural Pract. 2015;6(3):377-391. https://doi.org/10.4103/0976-3147.158768.

11. Smith PK. Rhinitis and cough. In: Bernstein JA, ed. Rhinitis and Related Upper Respiratory Conditions - A Clinical Guide. Springer; 2018:93-105. https://doi.org/10.1007/978-3-319-75370-6_9.

12. Song WJ, Morice AH. Cough hypersensitivity syndrome: a few more steps forward. Allergy, Asthma Immunol Res. 2017;9:394-402. https://doi.org/10.4168/aair.2017.9.5.394.

13. Chung KF. Approach to chronic cough: the neuropathic basis for cough hypersensitivity syndrome. J Thorac Dis. 2014;6(7):S699-S707. https://doi.org/10.3978/j.issn.2072-1439.2014.08.41.

14. Bonvini SJ, Birrell MA, Smith JA, Belvisi MG. Targeting TRP channels for chronic cough: from bench to bedside. Pharmacol Therapeut. 2019;2642. https://doi.org/10.1007/s00210-014-1082-1.

15. Zhang M, Wang S, Yu L, Xu X, Qiu Z. The role of ATP in cough hypersensitivity syndrome: new targets for treatment. J Thorac Dis. 2020;12(5):2781-2790. https://doi.org/10.21037/jtd-20-cough-001.

16. Turcotte SE, Lougheed MD. Cough in asthma. Curr Opin Pharmacol. 2011;11(3):231-237. https://doi.org/10.1016/j.coph.2011.04.008.

17. Niimi A, Fukumitsu K, Takeda N, Kanemitsu Y. Interfering with airway nerves in cough associated with asthma. Pulm Pharmacol Therapeut. 2019;59:101854. https://doi.org/10.1016/j.pupt.2019.101854.

18. Jatakanon A, Lalloo UG, Lim S, Chung KF, Barnes PJ. The role of ATP in cough hypersensitivity syndrome: new targets for treatment. J Thorac Dis. 2020;12(5):2781-2790. https://doi.org/10.21037/jtd-20-cough-001.

19. Chung KF. Approach to chronic cough: the neuropathic basis for cough hypersensitivity syndrome. J Thorac Dis. 2014;6(7):S699-S707. https://doi.org/10.3978/j.issn.2072-1439.2014.08.41.

20. Bao X, Bieger D, Hopkins DA, Miselis RR. Viscerotopic Representation of the Upper alimentary tract in the rat: sensory ganglia and nuclei of the solitary and spinal Trigeminal Tracts. J Comp Neurol. 1989;283(2):248-268. https://doi.org/10.1002/cne.902830207.

21. Altschuler SM, Bao X, Bieger D, Hopkins DA, Miselis RR. Viscerotopic Representation of the Upper alimentary tract in the rat: sensory ganglia and nuclei of the solitary and spinal Trigeminal Tracts. J Comp Neurol. 1989;283(2):248-268. https://doi.org/10.1002/cne.902830207.

22. Canning BJ, Mazzone SB, Meeker SN, Mori N, Reynolds SM, Undem BJ. Identification of the tracheal and laryngeal afferent neurons mediating cough in anaesthetized Guinea-pigs. J Physiol. 2004;557(2):543-558. https://doi.org/10.1113/jphysiol.2003.057885.

23. Chou YL, Mori N, Canning BJ. Opposing effects of bronchopulmonary C-fiber subtypes on cough in Guinea pigs. Am J Physiol Regul Integr Comp Physiol. 2018;314(3):489-498. https://doi.org/10.1152/ajpregu.00313.2017.

24. Canning BJ, Reynolds SM, Mazzone SB. Multiple mechanisms of reflex bronchospasm in Guinea pigs. J Appl Physiol. 2001;91:2642-2653. https://doi.org/10.1152/jappl.2001.91.6.2642.

25. Mazzone SB, Undem BJ. Vagal afferent innervation of the airways in health and disease. Physiol Rev. 2016;93(3):975-1024. https://doi.org/10.1152/physrev.00039.2015.

26. Gu Q, Lin Y-S, Lee L-Y. Epinephrine enhances the sensitivity of rat vagal chemosensitive neurons: role of β3-adrenoceptor. J Appl Physiol. 2007;102:1545-1555. https://doi.org/10.1038/jid.2014.371.

27. Lee LY, Pisarri TE. Afferent properties and reflex functions of bronchopulmonary C-fibers. Respir Physiol. 2001;125:47-65. https://doi.org/10.1016/S0034-5687(00)00204-8.

28. Lougheed MD, Turcotte SE, Fisher T. Cough variant asthma: lessons learned from deep inspirations. Lung. 2012;190:17-22. https://doi.org/10.1007/s00408-011-9348-6.

29. Moore BJ, Verburgt LM, King GG, Paré PD. The effect of deep inspiration on methacholine dose-response curves in normal subjects. Am J Respir Crit Care Med. 1997;156:1278-1281. https://doi.org/10.1164/ajrccm.156.4.96-11082.

30. Widdicombe J. Airway receptors. Respir Physiol Neurobiol. 2001;125(1-2):3-15. https://doi.org/10.1016/S0034-5687(00)00201-2.

31. Kollarik M, Undem BJ. Mechanisms of acid-induced activation of airway afferent nerve fibres in Guinea-pig. J Physiol. 2002;543(2):591-600. https://doi.org/10.1113/physiol.2002.022848.

32. McGovern AE, Driessen AK, Simmons DG, et al. Distinct brainstem and forebrain circuits receiving tracheal sensory neuron inputs revealed using a novel conditional anterograde transynaptic viral tracing system. J Neurosci. 2015;35:7041-7055. https://doi.org/10.1523/JNEUROSCI.5128-14.2015.

33. McGovern AE, Davis-Poynter N, Yang SK, Simmons DG, Farrell MJ, Mazzone SB. Evidence for multiple sensory circuits in the brain arising from the respiratory system: an anterograde viral tract tracing study in rodents. Brain Struct Funct. 2015;220:3683-3699. https://doi.org/10.1007/s00429-014-0883-9.

34. McGovern AE, Davis-Poynter N, Rakoczy J, Phipps S, Simmons DG, Mazzone SB. Anterograde neuronal circuit tracing using a genetically modified herpes simplex virus expressing EGFP. J Neurosci Methods. 2012;209:158-167. https://doi.org/10.1016/j.jneumeth.2012.05.035.

35. Mazzone SB, Cole LJ, Ando A, Egan GF, Farrell MJ. Investigation of the neural control of cough and cough suppression in humans using functional brain imaging. J Neurosci. 2011;31:2948-2958. https://doi.org/10.1523/JNEUROSCI.4597-10.2011.

36. Mazzone SB, McLennan L, McGovern AE, Egan GF, Farrell MJ. Representation of capsacin-evoked urge-to-cough in the human brain using functional magnetic resonance imaging. Am J Respir Crit Care Med. 2007;176:327-332. https://doi.org/10.1164/rccm.200612-1856OC.

37. Mazzone SB, Farrell MJ. Heterogeneity of cough neurobiology: clinical implications. Pulm Pharmacol Therapeut. 2019;55:62-66. https://doi.org/10.1016/j.pupt.2019.02.002.

38. Singh N, Driessen AK, McGovern AE, Moe AAk, Farrell MJ, Mazzone SB. Peripheral and central mechanisms of cough hypersensitivity. J Thorac Dis. 2020;12(9):5179-5193. https://doi.org/10.21037/jtd-2020-icc-007.

39. Cho PSP, Fletcher HV, Turner RD, Jolley CJ, Birring SS. Impaired cough suppression in chronic refractory cough. Eur
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2006;61(4):323-329. https://doi.org/10.1136/thoraxjnl-2005-102745.

Santagati R, Tsandramouras N, Holt K, et al. Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction. J Allergy Clin Immunol. 2017;139(3):771-779.e10. https://doi.org/10.1016/j.jaci.2016.04.045.

Driessen AK, McGovern AE, Narula M, et al. Central mechanisms of airway sensation and cough hypersensitivity. Pulm Pharmacol Therapeut. 2017;47:9-15. https://doi.org/10.1016/j.pupt.2017.01.010.

Tamasauskiene L, Sitkauskiene B. Immune system in the pathogenesis of chronic cough. Immunol Lett. 2020;218:40-43. https://doi.org/10.1016/j.imlet.2019.12.013.

Morice AH. Chronic cough hypersensitivity syndrome. Cough. 2013;9(14):7-10. https://doi.org/10.1186/1745-9974-9-14.

Chang AB, Gibson PG, Ardill J, McGarvey LPA. Calcitonin gene-related peptide relates to cough sensitivity in children with chronic cough. J Allergy Clin Immunol. 2020;145(1):243-249.e1. https://doi.org/10.1016/j.jaci.2019.12.048.

Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med. 2004;169(1):15-19. https://doi.org/10.1164/rccm.200308-1092oc.

Brightling CE. Cough due to asthma and nonasthmatic eosinophilic bronchitis. Lung. 2010;188(1):13-17. https://doi.org/10.1007/s00408-009-9163-5.

Morrow Brown H. Treatment of chronic asthma with prednisolone significance of eosinophils in the sputum. Lancet. 1958;272(7059):1245-1247. https://doi.org/10.1016/S0140-6736(58)91385-0.

McGarvey L, McKeagey P, Polley L, MacMahon J, Costello RW. Are there clinical features of a sensitized cough reflex? Pulm Pharmacol Therapeut. 2009;22(2):59-64. https://doi.org/10.1016/j.pupt.2008.11.003.

Meng J, Wang J, Steinhoff M, Dolly JO. TNFζ induces co-trafficking of TRPV1/1TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion. Sci Rep. 2016;6(September 2015):1-15. https://doi.org/10.1038/srep21226.

Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24(24):4211-4223. https://doi.org/10.1038/sj.emboj.7600893.

Schäfers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-α after spinal nerve ligation. J Neurosci. 2003;23(7):3028-3038. https://doi.org/10.1523/ jneurosci.23-07-03028.2003.

Wu LJ, Sweet TB, Clapham DE. International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev. 2010;62(3):381-404. https://doi.org/10.1124/pr.110.002725.

Belmonte C, Viana F. Molecular and cellular limits to somatosensory specificity. Mol Pain. 2008;4:14. https://doi.org/10.1186/1744-8069-4-14.

Lee L, Hsu C, Lin Y, Lin R, Khosravi M. Interaction between TRPA1 and TRPV1: synergy on pulmonary sensory nerves. Pulm Pharmacol Ther. 2015;35:87-93. https://doi.org/10.1016/j.pupt.2015.08.003 (Interaction).

Bonvini SJ, Belvisi MG. Cough and airway disease: the role of ion channels. Pulm Pharmacol Ther. 2017;47:21-28. https://doi.org/10.1016/j.pupt.2017.06.009.

Alenmyr L, Herrmann A, Högestätt ED, Greiff L, Zygmun PM. TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo. Clin Physiol Funct Imag. 2011;31(6):435-444. https://doi.org/10.1111/j.1475-097X.2011.01039.x.

Tian Q, Hu J, Xie C, et al. Recovery from tachyphylaxis of TRPV1 coincides with recycling to the surface membrane. Proc Natl Acad Sci U S A. 2019;116(11):5170-5175. https://doi.org/10.1073/pnas.1819635116.

Bousquet J, Czarlewski W, Zuberbier T, et al. Potential interplay between NFκB, TRPA1, and TRPV1 in nutrients for the control of COVID-19. Int Arch Allergy Immunol. 2021;182:324-338. https://doi.org/10.1159/000514204.
70. Gu Q, Lee LY. TRP channels in airway sensory nerves. Neurosci Lett. 2021;748(October 2020):135719. https://doi.org/10.1016/j.neulet.2021.135719.

71. Buday T, Brozmanova M, Biringerova Z, et al. Modulation of cough response by sensory inputs from the nose - role of trigeminal TRPA1 versus TRPM8 channels. Cough. 2012;8(1): 11. https://doi.org/10.1186/1746-9748-8-11.

72. Gavliakova S, Dolak T, Licha H, Krizova S, Plevkova J. Cineole, thymol and camphor nasal challenges and their effect on nasal symptoms and cough in an animal model. Acta Med Martiniana. 2013;13(2):5-13. https://doi.org/10.2478/acm-2013-0012.

73. Eccles R. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol Neurobiol. 2006;152(3):340-348. https://doi.org/10.1016/j.resp.2005.10.004.

74. Halfdanarson TR, Jatoi A. Chocolate as a cough suppressant: rationale and justification for an upcoming clinical trial. Support Cancer Ther. 2007;4(2):119-122. https://doi.org/10.3816/SCT.2007.n.006.

75. Cantero-Recasens G, Gonzalez JR, Fandos C, et al. Loss of function of transient receptor potential vanillid 1 (TRPV1) gene variant is associated with lower risk of active childhood asthma. J Biol Chem. 2010;285(36):27532-27535. https://doi.org/10.1074/jbc.C110.159491.

76. Smit LA, Kogevinas M, Antó JM, et al. Transient receptor potential vanillid-1 by insoluble particulate material and association with asthma. Am J Respir Cell Mol Biol. 2015;53(6):893-901. https://doi.org/10.1165/rcmb.2015-0086OC.

77. Smit LA, Kogevinas M, Antó JM, et al. Transient receptor potential genes, smoking, occupational exposures and cough in adults. Respir Res. 2012;13(1):26. https://doi.org/10.1186/1465-9921-13-26.

78. Deering-Rice CE, Shapiro D, Romero EG, et al. Activation of transient receptor potential ankyrin-1 by insoluble particulate material and association with asthma. Am J Respir Cell Mol Biol. 2015;53(6):893-901. https://doi.org/10.1165/rcmb.2015-0086OC.

79. Ternesten-Hasséus E, Johannson EL, Millqvist E. Cough reduction using capsaicin. Respir Med. 2015;109(1):27-37. https://doi.org/10.1016/j.rmed.2014.11.001.

80. Khalid S, Murdoch R, Newlands A, et al. P2X3 receptor antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Therapeut. 2019;56(January):56-62. https://doi.org/10.1016/j.pupt.2019.03.007.

81. McFarlane SB, McGarvey L. Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough. Clin Pharmacol Ther. 2021;109(3):619-636. https://doi.org/10.1002/cpt.2003.

82. McGovern AE, Short KR, Kywe Moe AA, Mcfarlane SB. Translational review: neuroimmune mechanisms in cough and emerging therapeutic targets. J Allergy Clin Immunol. 2018;142(5):1392-1402. https://doi.org/10.1016/j.jaci.2018.09.004.

83. Mc Govern AE, Short KR, Kywe Moe AA, Mcfarlane SB. Translational review: neuroimmune mechanisms in cough and emerging therapeutic targets. J Allergy Clin Immunol. 2018;142(5):1392-1402. https://doi.org/10.1016/j.jaci.2018.09.004.

84. Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanillioid subfamily type 1
immunoreactivities, and isoelectric B4 binding in primary afferent neurons of the rat and mouse. J Pain. 2007;8(3):263-272. https://doi.org/10.1016/j.jpain.2006.09.005.

100. Bíró T, Kovács L. An ice-Cold TR(i)P to skin biology: the role of TRPA1 in human epidermal keratinocytes. J Invest Dermatol. 2009;129(9):2096-2099. https://doi.org/10.1038/jid.2009.179.

101. Calixto JB, Kassuya CAL, André E, Ferreira J. Contribution of afferent neurons of the rat and mouse. Immunoreactivities, and isolectin B4 binding in primary. J Neurosci. 2004;11.008.

102. McNamara CR, Mandel-Brehm J, Bautista DM, et al. TRPA1 mediated formalin-induced pain. Proc Natl Acad Sci U S A. 2007;104(33):13525-13530. https://doi.org/10.1073/pnas.0705924104.

103. Bautista DM, Jordt SE, Nikai T, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006;124(6):1269-1282. https://doi.org/10.1016/j.cell.2006.02.023.

104. Pertovaara A, Koivisto A. TRPA1 ion channel in the spinal dorsal horn as a therapeutic target in central pain hypersensitivity and cutaneous neurogenic inflammation. Eur J Pharmacol. 2011;666(1-3):1-14. https://doi.org/10.1016/j.ejphar.2011.05.027.

105. Taylor-Clark TE, Ghatta S, Bettnier W, Undem BJ. Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol Pharmacol. 2009;75(4):820-829. https://doi.org/10.1124/mol.108.054445.

106. Bandell M, Story GM, Hwang SW, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-857. https://doi.org/10.1016/s0896-6273(04)00150-3. PMID: 15046718.

107. Malin S, Molliver D, Christianson JA, et al. TRPV1 and TRPA1 function and modulation are target tissue dependent. J Neurosci. 2011;31(29):10516-10528. https://doi.org/10.1523/JNEUROSCI.2992-10.2011.

108. Wilson SR, Nelson AM, Batia L, et al. The ion channel TRPA1 is required for chronic itch. J Neurosci. 2013;33(22):9283-9294. https://doi.org/10.1523/JNEUROSCI.5318-12.2013.

109. Akopian AN, Ruparel NB, Jeske NA, Hargreaves KM. Transient receptor potential TRPA1 channel desensitization in sensory neurons is agonist dependent and regulated by TRPV1-directed internalization. J Physiol. 2007;583(1):175-193. https://doi.org/10.1113/jphysiol.2007.133231.

110. Grace MS, Dubuis E, Birrell MA, Belvisi MG. Pre-clinical studies in cough research: role of transient receptor potential (TRP) channels (hVRL-2/mTRP12) by phorbol derivatives. Front Cell Neurosci. 2013;7(236):1-6. https://doi.org/10.3389/fncel.2013.00236.

111. Watanabe H, Davis JB, Smart D, et al. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002;277(16):13569-13577. https://doi.org/10.1074/jbc.M200062200.

112. Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7(236):1-6. https://doi.org/10.3389/fncel.2013.00236.

113. Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH. ATP P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol. 2004;514(1-3):158-161. https://doi.org/10.1016/j.ejphar.2004.11.008.

114. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011-1015. https://doi.org/10.1038/35093519.

115. Baxter M, Elton S, Dekkak B, et al. Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung. Thorax. 2014;69(12):1080-1089. https://doi.org/10.1136/thoraxjnl-2014-205467.

116. Leung SY, Niiii A, Williams AS, et al. Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in Guinea-pig. Cough. 2007;3(1):1-5. https://doi.org/10.1186/1745-9774-3-10.

117. Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH. Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dextromethorphan and chlorpheniramine. Exp Lung Res. 2008;34(10):681-693. https://doi.org/10.1080/01902140802339623.

118. Millqvist E. TRPV1 and TRPM8 in treatment of chronic cough. Pharmaceuticals. 2016;9(3):1-10. https://doi.org/10.3390/ ph9030045.

119. Plant TD, Strotmann R. TRPV4: a multifunctional nonselective cation channel with complex regulation. In: Liedtke WB, Heller SE, eds. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Taylor & Francis Group, LLC.; 2007.

120. Xiong H, Ling J, Chen M, Gu JG. Chemical and cold sensitivity of two distinct populations of TRPM8-expressing somatosensory neurons. J Neurophysiol. 2006;95(2):1221-1230. https://doi.org/10.1152/jn.01035.2005.

121. North RA. P2X3 receptors and peripheral pain mechanisms. J Physiol. 2004;554(2):301-308. https://doi.org/10.1113/jphysiol.2003.048587.

122. Kamei J, Takahashi Y. Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in Guinea pigs. Eur J Pharmacol. 2006;547(1-3):160-164. https://doi.org/10.1016/j.ejphar.2006.07.034.

123. Kamei J, Takahashi Y, Yoshikawa S, Saitoh A. Involvement of P2X2 receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol. 2005;528(1-3):158-161. https://doi.org/10.1016/j.ejphar.2005.10.030.

124. Parenti A, De Logu F, Gepetti P, Benemèi S. What is the evidence for the role of TRP channels in inflammatory and immune cells? Br J Pharmacol. 2016;173(6):953-969. https://doi.org/10.1111/bph.13392.

125. Bhattacharya MRC, Bautista DM, Wu K, Haeberle H, Lumpkin EA, Julius D. Radial stretch reveals distinct populations of mechanosensitive mammalian somatosensory
neurons. *Proc Natl Acad Sci U S A*. 2008;105(50):20015-20020. https://doi.org/10.1073/pnas.0810801105.

128. Vergnolle N, Cenac N, Altier C, et al. A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation. *Br J Pharmacol*. 2010;159(5):1161-1173. https://doi.org/10.1111/j.1476-5381.2009.00590.x.

129. Hamanaka K, Jian MY, Townsley MI, et al. TRPV4 channels augment macrophage activation and ventilator-induced lung injury. *Am J Physiol Lung Cell Mol Physiol*. 2010;299(3):353-362. https://doi.org/10.1152/ajplung.00315.2009.

130. Grace MS, Bonvini SJ, Belvisi MG, McIntyre P. Modulation of the TRPV4 ion channel as a therapeutic target for disease. *Pharmacol Ther*. 2017;177:9-22. https://doi.org/10.1016/j.pharmthera.2017.02.019.

131. Liu SC, Lu HH, Fan HC, et al. The identification of the TRPM8 channel on primary culture of human nasal epithelial cells and its response to cooling. *Med (United States)*. 2017;96(31):4-10. https://doi.org/10.1097/MD.0000000000007640.

132. Sabnis AS, Shadid M, Yost GS, Reilly CA. Human lung epithelial cells express a functional cold-sensing TRPM8 variant. *Am J Respir Cell Mol Biol*. 2008;39(4):466-474. https://doi.org/10.1165/rcmb.2007-0440OC.

133. Liu Y, Mikrani R, He Y, et al. TRPM8 channels: a review of distribution and clinical role. *Eur J Pharmacol*. 2020;882:173312. https://doi.org/10.1016/j.ejphar.2020.173312.

134. Tóth A, Czikora Á, Pásztor ET, et al. Vanilloid receptor-1 (TRPV1) expression and function in the vasculature of the rat. *J Histochem Cytochem*. 2014;62(2):129-144. https://doi.org/10.1369/jhc.2155413513589.

135. Xu M, Zhang Y, Wang M, et al. TRPV1 and TRPA1 in lung inflammation and airway hyperresponsiveness induced by fine particulate matter (PM2.5). *Oxid Med Cell Longev*. 2019;2019:1-15. https://doi.org/10.1155/2019/7450151.

136. Bertin S, Aoki-nonaka Y, Jong PR De, et al. The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4+ T cells. *Nat Immunol*. 2014;15(11):1055-1063. https://doi.org/10.1038/ni.3009.

137. Rahaman SO, Grove LM, Paruchuri S, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. *J Clin Invest*. 2014;124(12):5225-5238. https://doi.org/10.1172/JCI75331.

138. Liu SC, Lu HH, Cheng LH, et al. Identification of the cold receptor TRPM8 in the nasal mucosa. *Am J Rhinol Allergy*. 2015;29(4):e112-e116. https://doi.org/10.2500/ajra.2015.29.4202.

139. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. *Int Rev Cytol*. 2004;240:31-304. https://doi.org/10.1016/S0074-7696(04)40002-3.

140. Huang YA, Stone LM, Pereira E, et al. Knocking out P2X receptors reduces transmitter secretion in taste buds. *J Neurosci*. 2011;31(38):13654-13661. https://doi.org/10.1523/JNEUROSCI.3356-11.2011.

141. Zhu G, , ICGN Investigators, Gulsvik A, Bakke P, et al. Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. *Hum Mol Genet*. 2009;18(11):2053-2062. https://doi.org/10.1093/hmg/ddp111.

142. Xiong M, Wang J, Guo M, Zhou Q, Lu W. TRPM8 genetic variations associated with COPD risk in the Chinese Han population. *Int J COPD*. 2016;11(1):2563-2571. https://doi.org/10.2147/COPD.S109026.